Ernst Ulsperger

1.3k total citations
45 papers, 887 citations indexed

About

Ernst Ulsperger is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Ernst Ulsperger has authored 45 papers receiving a total of 887 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 13 papers in Molecular Biology. Recurrent topics in Ernst Ulsperger's work include Lung Cancer Research Studies (18 papers), Lung Cancer Treatments and Mutations (13 papers) and Neuroendocrine Tumor Research Advances (11 papers). Ernst Ulsperger is often cited by papers focused on Lung Cancer Research Studies (18 papers), Lung Cancer Treatments and Mutations (13 papers) and Neuroendocrine Tumor Research Advances (11 papers). Ernst Ulsperger collaborates with scholars based in Austria, Germany and United Kingdom. Ernst Ulsperger's co-authors include Gerhard Hamilton, Gerhard Baumgartner, K Karrer, Barbara H. Rath, Lama Sakr, Robert Zeillinger, Valentina Tzekova, M. Wenczl, Rodryg Ramlau and N. Ghilezan and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Scientific Reports.

In The Last Decade

Ernst Ulsperger

43 papers receiving 861 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ernst Ulsperger Austria 15 572 360 248 126 100 45 887
L. A. Hammond United States 17 472 0.8× 320 0.9× 418 1.7× 109 0.9× 95 0.9× 29 981
Andreas Varkaris United States 17 331 0.6× 327 0.9× 393 1.6× 253 2.0× 65 0.7× 46 836
Mónica Musteanu Spain 14 552 1.0× 149 0.4× 415 1.7× 181 1.4× 119 1.2× 32 972
Hirokazu Tanino Japan 17 415 0.7× 208 0.6× 324 1.3× 176 1.4× 48 0.5× 81 980
Ken Tajima Japan 17 328 0.6× 295 0.8× 498 2.0× 240 1.9× 52 0.5× 38 927
Ruth O’Regan United States 11 453 0.8× 220 0.6× 234 0.9× 335 2.7× 92 0.9× 34 907
Justine Y. Bruce United States 16 329 0.6× 275 0.8× 413 1.7× 175 1.4× 48 0.5× 73 955
Adam Kresak United States 14 366 0.6× 192 0.5× 302 1.2× 95 0.8× 176 1.8× 32 676
Simone Steinbild Germany 12 488 0.9× 263 0.7× 353 1.4× 147 1.2× 30 0.3× 19 863
Renata Duchnowska Poland 18 719 1.3× 530 1.5× 309 1.2× 155 1.2× 31 0.3× 68 1.1k

Countries citing papers authored by Ernst Ulsperger

Since Specialization
Citations

This map shows the geographic impact of Ernst Ulsperger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ernst Ulsperger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ernst Ulsperger more than expected).

Fields of papers citing papers by Ernst Ulsperger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ernst Ulsperger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ernst Ulsperger. The network helps show where Ernst Ulsperger may publish in the future.

Co-authorship network of co-authors of Ernst Ulsperger

This figure shows the co-authorship network connecting the top 25 collaborators of Ernst Ulsperger. A scholar is included among the top collaborators of Ernst Ulsperger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ernst Ulsperger. Ernst Ulsperger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rath, Barbara H., Lukas Klameth, Maximilian J. Hochmair, et al.. (2023). Small cell lung cancer: circulating tumor cell lines and expression of mediators of angiogenesis and coagulation. SHILAP Revista de lepidopterología. 4(2). 355–365. 4 indexed citations
2.
Hochmair, Maximilian J., Barbara H. Rath, Lukas Klameth, et al.. (2019). Effects of salinomycin and niclosamide on small cell lung cancer and small cell lung cancer circulating tumor cell lines. Investigational New Drugs. 38(4). 946–955. 14 indexed citations
3.
Klameth, Lukas, Barbara H. Rath, Doris Moser, et al.. (2017). Small cell lung cancer: model of circulating tumor cell tumorospheres in chemoresistance. Scientific Reports. 7(1). 5337–5337. 71 indexed citations
4.
Hamilton, Gerhard, Barbara H. Rath, & Ernst Ulsperger. (2015). How to target small cell lung cancer. Oncoscience. 2(8). 684–692. 8 indexed citations
5.
Manegold, Christian, Johan Vansteenkiste, Felipe Cardenal, et al.. (2012). Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer. Investigational New Drugs. 31(1). 175–182. 52 indexed citations
6.
Fiebiger, Wolfgang, Ulrike Olszewski, Ernst Ulsperger, Klaus Geißler, & Gerhard Hamilton. (2011). In vitro cytotoxicity of novel platinum-based drugs and dichloroacetate against lung carcinoid cell lines. Clinical & Translational Oncology. 13(1). 43–49. 34 indexed citations
7.
Czejka, Martin, et al.. (2010). Evidence for the conversion of docetaxel into 7’-epidocetaxel in patients receiving Taxotere®-based conventional chemotherapy. International Journal of Clinical Pharmacology and Therapeutics. 48(7). 483–484. 5 indexed citations
8.
Manegold, Christian, Johan Vansteenkiste, Felipe Cardenal, et al.. (2009). A randomized, parallel-group, phase II study to evaluate the efficacy and safety of three doses of the integrin inhibitor cilengitide compared with docetaxel in patients with stage IV non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy. Journal of Thoracic Oncology. 4(9). 1 indexed citations
9.
Fridrik, Michael, H. Hausmaninger, Alois Lang, et al.. (2009). Dose-dense therapy improves survival in aggressive non-Hodgkin’s lymphoma. Annals of Hematology. 89(3). 273–282. 4 indexed citations
10.
11.
Brodowicz, Thomas, Maciej Krzakowski, Matjaž Zwitter, et al.. (2006). Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial. Lung Cancer. 52(2). 155–163. 256 indexed citations
12.
13.
Theyer, Gerhard, Ernst Ulsperger, George Baumgartner, Markus Raderer, & Gerhard Hamilton. (2000). Prolonged response to a single androgen suppression phase in a subpopulation of prostate cancer patients. Annals of Oncology. 11(7). 877–881. 6 indexed citations
14.
Hamilton, Gerhard, et al.. (2000). Metabolism of camptothecin, a potent topoisomerase I inhibitor, in the isolated perfused rat liver. Cancer Chemotherapy and Pharmacology. 45(1). 50–54. 11 indexed citations
15.
16.
Haberl, I, Katharina Schaufler, Ernst Ulsperger, et al.. (1998). P-glycoprotein-mediated multidrug resistance is modulated by pretreatment with chemosensitizers in HCT-8 carcinoma cells in vitro.. International Journal of Oncology. 12(5). 1137–42. 7 indexed citations
17.
Karrer, K & Ernst Ulsperger. (1995). Surgery For Cure Followed By Chemotherapy In Small Cell Carcinoma Of The Lung: For The Isc-Lung Cancer Study Group. Acta Oncologica. 34(7). 899–906. 35 indexed citations
18.
Ulsperger, Ernst, H. Rainer, Gershon Y. Locker, et al.. (1993). Adjuvant Vaccination in Colorectal Carcinoma. Annals of the New York Academy of Sciences. 690(1). 360–363. 2 indexed citations
19.
Ulsperger, Ernst, et al.. (1991). Multimodality treatment for small cell bronchial carcinoma *1, *2Preliminary results of a prospective, multicenter trial. European Journal of Cardio-Thoracic Surgery. 5(6). 306–310. 18 indexed citations
20.
Ulsperger, Ernst & K Karrer. (1989). Diagnostic and prognostic importance of tumor markers in lung cancer.. PubMed. 126(1). 21–31. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by L. A. Hammond Breakdown of academic impact, for papers by Andreas Varkaris Breakdown of academic impact, for papers by Mónica Musteanu Breakdown of academic impact, for papers by Hirokazu Tanino Breakdown of academic impact, for papers by Ken Tajima Breakdown of academic impact, for papers by Ruth O’Regan Breakdown of academic impact, for papers by Justine Y. Bruce Breakdown of academic impact, for papers by Adam Kresak Breakdown of academic impact, for papers by Simone Steinbild Breakdown of academic impact, for papers by Renata Duchnowska
Rankless by CCL
2026